Digital Therapeutics Companies Are Running Clinical Operations on Startup Headcount
The digital therapeutics (DTx) sector entered a pivotal commercial phase in 2025, with the FDA's Software as a Medical Device (SaMD) regulatory pathway and the emerging Prescription Digital Therapeutics (PDT) authorization model creating both opportunity and operational pressure. Companies pursuing de novo FDA authorization for cognitive behavioral therapy apps, digital diabetes management tools, or substance use disorder platforms are managing regulatory evidence requirements comparable to traditional pharmaceutical submissions — but with the headcount of a software startup.
A 2025 report by the Digital Therapeutics Alliance found that the average DTx company preparing for FDA submission employed 28 full-time staff, of whom approximately six were involved in clinical operations. These small clinical teams are simultaneously managing ongoing clinical studies, patient recruitment pipelines, IRB correspondence, and pre-submission regulatory filings — a combination that independent researchers at Stanford's Digital Health Program noted generates administrative overload "structurally incompatible with the pace of evidence generation required for competitive market entry."
Three VA Functions That Directly Accelerate DTx Commercialization
Clinical study coordination for DTx companies covers the operational backbone of ongoing pivotal or supportive studies: site coordinator scheduling, patient session tracking, data collection follow-up, adverse event documentation routing, and protocol deviation logging. Many DTx trials are decentralized or fully remote, which increases the volume of asynchronous communication events per enrolled patient. VAs manage this communication and tracking layer, ensuring that no patient touchpoint falls through the cracks and that study documentation remains audit-ready.
Patient recruitment communication is among the most resource-intensive phases of any DTx clinical program. VAs manage outreach sequences to potential participants identified through healthcare system partners or digital advertising channels, schedule screening calls, send enrollment documentation, and maintain communication with participants through the consent and baseline assessment process. Recruitment bottlenecks are the leading cause of DTx trial delays, according to the 2024 SCOPE Summit findings — and most of the causes are administrative rather than clinical.
Regulatory filing support covers the coordination layer around pre-submission meetings with FDA, Q-Submission package assembly, De Novo petition document organization, and labeling review scheduling. VAs do not draft regulatory strategy or write submissions — that requires qualified RA professionals — but they manage the document collection, version tracking, deadline calendar, and internal review routing that keeps the submission process on schedule. This support function is particularly valuable during the weeks immediately preceding a submission deadline when simultaneous document streams converge.
The Funding Pressure Context
DTx companies raised approximately $1.2 billion in venture funding in 2024, but investor expectations around milestone-driven funding tranches have tightened. Delays in clinical study enrollment or regulatory submission timelines directly affect valuation at the next funding round. Companies that can demonstrate on-schedule study execution and clean regulatory documentation histories command stronger negotiating positions with Series B and C investors.
A 2025 analysis by Rock Health found that DTx companies with disciplined operational infrastructure — defined as documented workflows, clear staff-to-patient ratios, and systematic milestone tracking — were 31% more likely to achieve funding milestones on schedule than operationally ad hoc peers.
Building the Administrative Layer Early
DTx companies that establish VA-supported coordination workflows before their pivotal study enrollment phase build scalable process infrastructure that carries forward through commercialization. The same workflows used to manage clinical study patient communication can be adapted for post-market patient onboarding and provider engagement programs.
For digital therapeutics companies balancing clinical evidence generation with regulatory filing timelines, Stealth Agents provides trained virtual assistants with DTx-specific coordination expertise.
Sources
- Digital Therapeutics Alliance, State of the DTx Industry 2025, dtxalliance.org
- Stanford Digital Health Program, Operational Constraints in Early-Stage DTx Companies, digitalhealth.stanford.edu, 2025
- SCOPE Summit, 2024 Clinical Trial Recruitment Benchmark Findings, scopesummit.com
- Rock Health, Digital Health Funding Report 2025, rockhealth.com
- FDA, Software as a Medical Device (SaMD) Action Plan, fda.gov